

DAFTAR PUSTAKA

1. Ahmed, S. *et al.* (2014) ‘Advances in the management of colorectal cancer: From biology to treatment’, *International Journal of Colorectal Disease*, 29(9), pp. 1031–1042. doi: 10.1007/s00384-014-1928-5.
2. Ajouz, H., Mukherji, D. and Shamseddine, A. (2014) ‘Secondary bile acids: An underrecognized cause of colon cancer’, *World Journal of Surgical Oncology*, 12(1), pp. 1–5. doi: 10.1186/1477-7819-12-164.
3. Alzahrani, S. M., Al Doghaither, H. A. and Al-Ghafar, A. B. (2021) ‘General insight into cancer: An overview of colorectal cancer (review)’, *Molecular and Clinical Oncology*, 15(6). doi: 10.3892/MCO.2021.2433.
4. Amersi, F., Agustin, M. and Ko, C. Y. (2006) ‘Colorectal cancer: Epidemiology and health services research’, *Surgical Oncology Clinics of North America*, 15(1), pp. 21–37. doi: 10.1016/j.soc.2005.08.003.
5. Annaházi, A. *et al.* (2013) ‘Fecal MMP-9: A new noninvasive differential diagnostic and activity marker in ulcerative colitis’, *Inflammatory Bowel Diseases*, 19(2), pp. 316–320. doi: 10.1002/ibd.22996.
6. Aran, V. *et al.* (2016) ‘Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality’, *Clinical Colorectal Cancer*, 15(3), pp. 195–203. doi: 10.1016/j.clcc.2016.02.008.
7. Arnold, M. *et al.* (2017) ‘Global patterns and trends in colorectal cancer incidence and mortality’, *Gut*, 66(4), pp. 683–691. doi: 10.1136/gutjnl-2015-310912.
8. Arshita, N. *et al.* (2018) ‘The tendency of having MSH2 and MSH6 microsatellite instability among clinicopathological features in patients with colorectal cancer’, *Asian Pacific Journal of Cancer Prevention*, 19(11), pp. 3147–3152. doi: 10.31557/APJCP.2018.19.11.3147.
9. Bahardoust, M. *et al.* (2023) ‘The Association between ABO Blood Group and the Risk of Colorectal Cancer: A Systematic Literature Review and Meta-Analysis’, *Asian Pacific Journal of Cancer Prevention*, 24(8), pp. 2555–2563. doi: 10.31557/APJCP.2023.24.8.2555.
1. M. *et al.* (2009) ‘Microsatellite instability predicts improved response to py with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer



and leukemia group B protocol 89803', *Journal of Clinical Oncology*, 27(11), pp. 1814–1821. doi: 10.1200/JCO.2008.18.2071.

11. Bertero, L. *et al.* (2018) 'Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?', *Virchows Archiv*, 472(4), pp. 519–531. doi: 10.1007/s00428-017-2276-y.
12. Bevan, R. and Rutter, M. D. (2018) 'Colorectal Cancer Screening — Who , How , and When ?', *Clin Endosc*, 51, pp. 37–49.
13. Bhattarai, M. *et al.* (2020) 'MLH1 and MSH2 mismatch repair protein profile using immunohistochemistry in Nepalese colorectal cancer patients', *Medical Journal of Indonesia*, 29(2), pp. 183–189. doi: 10.13181/mji.oa.203633.
14. Brar, B. *et al.* (2021) 'Nanotechnology in Colorectal Cancer for Precision Diagnosis and Therapy', *Frontiers in Nanotechnology*, 3(September), pp. 1–21. doi: 10.3389/fnano.2021.699266.
15. Bray, F. *et al.* (2015) 'Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration', *International Journal of Cancer*, 137(9), pp. 2060–2071. doi: 10.1002/ijc.29670.
16. Bronchud, M. *et al.* (2000) 'Molecular Basis of Cancer', *The Lancet*, 356(Oct 14), p. 2000. doi: 10.1016/s0140-6736(05)74283-5.
17. Brown, K. G. M. *et al.* (2019) 'Management of colorectal cancer', *The BMJ*, 366(August), pp. 1–7. doi: 10.1136/bmj.l4561.
18. Brzacki, V. *et al.* (2019) 'Diabetes Mellitus: a Clinical Condition Associated with Metabolic Syndrome and Colorectal Cancer Risk', *Current Pharmacology Reports*, 5(4), pp. 205–209. doi: 10.1007/s40495-019-00183-8.
19. Carethers, J. M. and Doubeni, C. A. (2020) 'Causes of Socioeconomic Disparities in Colorectal Cancer and Intervention Framework and Strategies', *Gastroenterology*, 158(2), pp. 354–367. doi: 10.1053/j.gastro.2019.10.029.
20. Carr, P. R. *et al.* (2018) 'Lifestyle factors and risk of sporadic colorectal cancer by instability status: A systematic review and meta-analyses', *Annals of Oncology*, –834. doi: 10.1093/annonc/mdy059.
- (2023) 'Estimates and Projections of the Global Economic Cost of 29 Cancers and Territories from 2020 to 2050', *JAMA Oncology*, 9(4), pp. 465–472. doi:



10.1001/jamaoncol.2022.7826.

22. Cheng, Y., Ling, Z. and Li, L. (2020) 'The Intestinal Microbiota and Colorectal Cancer', *Frontiers in Immunology*, 11(November), pp. 1–13. doi: 10.3389/fimmu.2020.615056.
23. Chowdhury, M. R. *et al.* (2024) 'Optimizing Fecal Occult Blood Test (FOBT) Colorectal Cancer Screening Using Gut Bacteriome as a Biomarker', *Clinical Colorectal Cancer*, 23(1), pp. 22–34.e2. doi: 10.1016/j.clcc.2023.10.004.
24. Cisterna, B. A. *et al.* (2016) 'Targeted nanoparticles for colorectal cancer', *Nanomedicine*, 11(18), pp. 2443–2456. doi: 10.2217/nnm-2016-0194.
25. Daly, M. C. and Paquette, I. M. (2019) 'Surveillance, Epidemiology, and End Results (SEER) and SEER-Medicare Databases: Use in Clinical Research for Improving Colorectal Cancer Outcomes', *Clinics in Colon and Rectal Surgery*, 32(1), pp. 61–68. doi: 10.1055/s-0038-1673355.
26. Dong, L. *et al.* (2021) 'Cytoplasmic MSH2 Related to Genomic Deletions in the MSH2/EPCAM Genes in Colorectal Cancer Patients With Suspected Lynch Syndrome', *Frontiers in Oncology*, 11(May), pp. 1–11. doi: 10.3389/fonc.2021.627460.
27. Ekundina, V. . *et al.* (2023) 'Immunohistochemical Expression of MSH6 and MSH2 in Colorectal Cancer', *Archives of Medical Case Reports and Case Study*, 7(January). doi: 10.31579/2692-9392/170.
28. Ferlay, J. *et al.* (2021) 'Cancer statistics for the year 2020: An overview', *International Journal of Cancer*, 149(4), pp. 778–789. doi: 10.1002/ijc.33588.
29. Fleming, M. *et al.* (2012) 'Colorectal carcinoma: Pathologic aspects', *Journal of Gastrointestinal Oncology*, 3(3), pp. 153–173. doi: 10.3978/j.issn.2078-6891.2012.030.
30. Ford, A. C. *et al.* (2008) 'Diagnostic utility of alarm features for colorectal cancer: Systematic review and meta-analysis', *Gut*, 57(11), pp. 1545–1552. doi: 10.1136/gut.2008.159723.
31. Gandomani, H. S. *et al.* (2017) 'Colorectal cancer in the world: incidence, mortality and risk factors', *Biomedical Research and Therapy*, 4(10), p. 1656. doi: 10.15419/bmrat.v4i10.372.
32. Guo, L. *et al.* (2023) 'Correlation of MLH1 and MSH2 levels with clinicopathologic in colorectal cancer', *Am J Transl Res*, 15(2), pp. 1107–1116. Available at: <https://doi.org/10.21960/ajtr.2023.1502.0007>.
33. National Cancer Center, N. (2020) 'Recommendations for Follow-Up after Colonoscopy and Polypectomy: Update by the US Multi-Society Task Force on Colorectal Cancer', *American*



- Journal of Gastroenterology*, 115(3), pp. 415–434. doi: 10.14309/ajg.0000000000000544.
34. Guraya, S. (2014) ‘Chemopreventive role of vitamin D in colorectal carcinoma’, *Journal of Microscopy and Ultrastructure*, 2(1), p. 1. doi: 10.1016/j.jmau.2013.09.001.
 35. Hammond, W. A., Swaika, A. and Mody, K. (2016) ‘Pharmacologic resistance in colorectal cancer: A review’, *Therapeutic Advances in Medical Oncology*, 8(1), pp. 57–84. doi: 10.1177/1758834015614530.
 36. Hnatyszyn, A. et al. (2019) ‘Colorectal carcinoma in the course of inflammatory bowel diseases’, *Hereditary Cancer in Clinical Practice*, 17(1), pp. 1–9. doi: 10.1186/s13053-019-0118-4.
 37. Hossain, M. S. et al. (2022) ‘Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies’, *Cancer*, 14(1732), pp. 1–25.
 38. Howe, J. R. and Guillem, J. G. (1997) ‘The genetics of colorectal cancer’, *Surgical Clinics of North America*, 77(1), pp. 175–179. doi: 10.1007/978-1-4614-8412-7_1.
 39. Hu, X. et al. (2018) ‘Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers’, *Chinese Journal of Pathology*, 47(11), pp. 827–833. doi: 10.3760/cma.j.issn.0529-5807.2018.11.003.
 40. Huyghe, N. et al. (2022) ‘Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine’, *Cancers*, 14(9). doi: 10.3390/cancers14092241.
 41. Issa, I. A. and Noureddine, M. (2017) ‘Colorectal cancer screening: An updated review of the available options’, *World Journal of Gastroenterology*, 23(28), pp. 5086–5096. doi: 10.3748/wjg.v23.i28.5086.
 42. Jaballah-Gabteni, A. et al. (2019) ‘Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: Investigation of a Tunisian Lynch syndrome family with discordant twins’, *Journal of Translational Medicine*, 17(1), pp. 1–13. doi: 10.1186/s12967-019-1961-9.



Subrata, F. (2020) ‘The Survival Rate of Colorectal Cancer in dr. Cipto
 10 Hospital’, *The New Ropanasuri : Journal of Surgery*, 5(2), pp. 13–17. doi:
 5i2.1081.

and Sukor, N. F. (2020) ‘Colorectal Cancer Immunotherapy: Options and

Strategies', *Frontiers in Immunology*, 11(September), pp. 1–18. doi: 10.3389/fimmu.2020.01624.

45. Kenney, B., Deng, Y. and Mitchell, K. (2013) 'Expression of p27, COX-2, MLH1, and MSH2 in young patients with colon carcinoma and correlation with morphologic findings', *Human Pathology*, 44(4), pp. 591–597. doi: 10.1016/j.humpath.2012.07.003.
46. Keum, N. N. and Giovannucci, E. (2019) 'Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies', *Nature Reviews Gastroenterology and Hepatology*, 16(12), pp. 713–732. doi: 10.1038/s41575-019-0189-8.
47. Kitsel, Y. *et al.* (2023) 'Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies', *Cancers*, 15(6), p. 1679. doi: 10.3390/cancers15061679.
48. Kolligs, F. T. (2016) 'Diagnostics and epidemiology of colorectal cancer', *Visceral Medicine*, 32(3), pp. 158–164. doi: 10.1159/000446488.
49. Kranenburg, O., Speeten, K. van der and Hingh, I. de (2021) 'Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges', *Frontiers in Oncology*, 11(March), pp. 1–11. doi: 10.3389/fonc.2021.650098.
50. Krasteva, N. and Georgieva, M. (2022) 'Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials', *Pharmaceutics*, 14(6), pp. 1–38. doi: 10.3390/pharmaceutics14061213.
51. Lanza, G. *et al.* (2006) 'Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients', *Journal of Clinical Oncology*, 24(15), pp. 2359–2367. doi: 10.1200/JCO.2005.03.2433.
52. Lanza, G. *et al.* (2007) 'mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer', *Molecular Cancer*, 6, pp. 1–11. doi: 10.1186/1476-4598-6-54.
53. Lawler, M. *et al.* (2019) *Colorectal Cancer*. Sixth Edit, *Abeloff's Clinical Oncology*. Sixth Edit. Elsevier Inc. doi: 10.1016/B978-0-323-47674-4.00074-8.
54. Van Lier, M. G. F. *et al.* (2012) *Peutz-Jeghers syndrome and family planning: The attitude towards prenatal diagnosis and pre-implantation genetic diagnosis*, *European Journal of*

ics. doi: 10.1038/ejhg.2011.152.

(2017) *Faktor Resiko Terjadinya Kanker Kolorektal di Indonesia*. Hasanuddin

(2018) 'Type 2 diabetes and risk of colorectal cancer in two large U.S. prospective



- cohorts', *British Journal of Cancer*, 119(11), pp. 1436–1442. doi: 10.1038/s41416-018-0314-4.
57. Makmun, D. *et al.* (2014) 'Changing trends in gastrointestinal malignancy in Indonesia: The Jakarta experience', *Journal of Cancer Research & Therapy*, 2(9), pp. 160–168. doi: 10.14312/2052-4994.2014-24.
58. Mármol, I. *et al.* (2017) 'Colorectal carcinoma: A general overview and future perspectives in colorectal cancer', *International Journal of Molecular Sciences*, 18(1). doi: 10.3390/ijms18010197.
59. Mendis, S. *et al.* (2022) 'Biology and Clinical Implications of Fecal Occult Blood Test Screen-Detected Colorectal Cancer', *JNCI Cancer Spectrum*, 6(1), pp. 1–10. doi: 10.1093/jncics/pkab100.
60. Mohamed, S. A.-A. *et al.* (2023) 'Expression status of MLH1 and MSH2 mismatch repair proteins in colorectal carcinoma', *Egyptian Journal of Pathology*, 43(1), pp. 8–13. doi: 10.4103/egjp.egjp_1_23.
61. Morgan, E. *et al.* (2020) 'Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN', *Gut*, 72(2).
62. Nagtegaal, I. D. *et al.* (2020) 'The 2019 WHO classification of tumours of the digestive system', *Histopathology*, 76(2), pp. 182–188. doi: 10.1111/his.13975.
63. National Cancer Institute (2022) 'Financial Burden of Cancer Care', *Cancer Trends Progress Report*, Updated Ap. Available at: https://progressreport.cancer.gov/after/economic_burden#field_most_recent_estimates.
64. Nguyen, T. T. *et al.* (2018) 'Role of bile acids in colon carcinogenesis', *World J Clin Cases*, 9(9), pp. 157–164.
65. Nojadeh, J. N., Sharif, S. B. and Sakhinia, E. (2018) 'Microsatellite instability in colorectal cancer', *EXCLI Journal*, 17, pp. 159–168. doi: 10.17179/excli2017-948.
66. Palimaka, S., Blackhouse, G. and Goeree, R. (2015) 'Colon capsule endoscopy for the detection of colorectal polyps: An economic analysis', *Ontario Health Technology Assessment*, pp. 1–43.
- (2018) 'Diabetes, plasma glucose and incidence of colorectal cancer in Chinese pective study of 0.5 million people', *Journal of Epidemiology and Community*, pp. 919–925. doi: 10.1136/jech-2018-210651.



68. Peeters, P. J. H. L. *et al.* (2015) 'The risk of colorectal cancer in patients with type 2 Diabetes: Associations with treatment stage and obesity', *Diabetes Care*, 38(3), pp. 495–502. doi: 10.2337/dc14-1175.
69. Price, S. and Wilson, L. (2016) *Patofisiologi Konsep Klinis dan Proses-Proses Penyakit*. 6th edn. Jakarta: Penerbit Buku KEdokteran EGC.
70. Purnomo, H. D. *et al.* (2023) 'Colorectal cancer screening in Semarang, Indonesia: A multicenter primary health care based study', *PLoS ONE*, 18(1 January), pp. 1–12. doi: 10.1371/journal.pone.0279570.
71. Randrian, V., Evrard, C. and Tougeron, D. (2021) 'Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies', *Cancers*, 13(12), pp. 1–18.
72. Rashid, G. *et al.* (2023) 'ABO and Rhesus blood group markers as predictors in colorectal cancer: A prospective observational study', *Medicine (United States)*, 102(47), p. E36256. doi: 10.1097/MD.00000000000036256.
73. Rawla, P., Sunkara, T. and Barsouk, A. (2019) 'Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors', *Przegląd Gastroenterologiczny*, 14(2), pp. 89–103. doi: 10.5114/pg.2018.81072.
74. Sawicki, T. *et al.* (2021) 'A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis', *Cancers*, 13(9), pp. 1–23. doi: 10.3390/cancers13092025.
75. Schreuders, E. H. *et al.* (2015) 'Colorectal cancer screening: A global overview of existing programmes', *Gut*, 64(10), pp. 1637–1649. doi: 10.1136/gutjnl-2014-309086.
76. Sehgal, R. *et al.* (2014) 'Lynch Syndrome: An updated review', *Genes*, 5(3), pp. 497–507. doi: 10.3390/genes5030497.
77. Shussman, N. and Wexner, S. D. (2014) 'Colorectal polyps and polyposis syndromes', *Gastroenterology Report*, 2(1), pp. 1–15. doi: 10.1093/gastro/got041.
78. Siena, S. *et al.* (2009) 'Biomarkers predicting clinical outcome of epidermal growth factor
ted therapy in metastatic colorectal cancer', *Journal of the National Cancer*
19), pp. 1308–1324. doi: 10.1093/jnci/djp280.
. *et al.* (2023) 'A Novel Mutation of MSH2 Gene in a Patient with Lynch
esenting with Thirteen Metachronous Malignancies', *Journal of Clinical*



Medicine, 12(17). doi: 10.3390/jcm12175502.

80. Sugiyono (2021) *Metode penelitian kuantitatif, kualitatif, dan R&D*. 3rd edn. Bandung: Alfabeta.
81. Sung, H. *et al.* (2021a) ‘Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, *CA: A Cancer Journal for Clinicians*, 71(3), pp. 209–249. doi: 10.3322/caac.21660.
82. Sung, H. *et al.* (2021b) ‘Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, *CA: A Cancer Journal for Clinicians*, 71(3), pp. 209–249. doi: 10.3322/caac.21660.
83. Tariq, K. and Ghias, K. (2016) ‘Colorectal cancer carcinogenesis: a review of mechanisms’, *Cancer Biology and Medicine*, 13(1), pp. 120–135. doi: 10.28092/j.issn.2095-3941.2015.0103.
84. Thélin, C. and Sikka, S. (2015) ‘Epidemiology of Colorectal Cancer — Incidence, Lifetime Risk Factors Statistics and Temporal Trends’, *Screening for Colorectal Cancer with Colonoscopy*, (Table 1). doi: 10.5772/61945.
85. Valle, L. *et al.* (2019) ‘Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine’, *J Pathol*, 247(5), pp. 574–588. doi: 10.1002/path.5229.Genetic.
86. Wang, S. M. *et al.* (2019) ‘Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer’, *World Journal of Gastrointestinal Oncology*, 11(11), pp. 1065–1080. doi: 10.4251/wjgo.v11.i11.1065.
87. WHO (2020) *Cancer Indonesia 2020 Country Profile, Cancer Country Profile*. doi: 10.1016/S0366-0850(07)80117-7.
88. Win, A. K. *et al.* (2012) ‘Risk prediction models for colorectal cancer: A review’, *Cancer Epidemiology Biomarkers and Prevention*, 21(3), pp. 398–410. doi: 10.1158/1055-9965.EPI-11-0771.
89. Wong, M. C. S. *et al.* (2021) ‘Differences in Incidence and Mortality Trends of Colorectal Cancer Worldwide Based on Sex, Age, and Anatomic Location’, *Clinical Gastroenterology*, 19(5), pp. 955-966.e61. doi: 10.1016/j.cgh.2020.02.026.



Organisation (2020) *World Health Statistics 2020: Monitoring Health for the Sustainable Development Goals*. Available at: <https://all3dp.com/2/fused-deposition-3d-printing-simply-explained/>.

91. Young, P. E. *et al.* (2014) 'Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: Current status and challenges', *Journal of Cancer*, 5(4), pp. 262–271. doi: 10.7150/jca.7988.
92. Zhang, Y. *et al.* (2017) 'Cholecystectomy can increase the risk of colorectal cancer: A meta-analysis of 10 cohort studies', *PLoS ONE*, 12(8), pp. 1–17. doi: 10.1371/journal.pone.0181852.
93. Zheng, S. *et al.* (2023) 'Effectiveness of Colorectal Cancer (CRC) Screening on All-Cause and CRC-Specific Mortality Reduction: A Systematic Review and Meta-Analysis', *Cancers*, 15(7). doi: 10.3390/cancers15071948.

